Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010–2014

International Journal of Infectious Diseases

Volumn 49, Issue , 2016, Pages 141-148

  Tärnberg, Maria ^a   Nilsson, Lennart E ^a   Dowzicky, Michael J ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial resistance; Global; Skin and skin structure infections; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; SKIN;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SKIN; SKIN DISEASES, BACTERIAL;

EID: 84978438325     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.06.016     Document Type: Article

References (36)

1. 1 Eron, L.J., Lipsky, B.A., Low, D.E., Nathwani, D., Tice, A.D., Volturo, G.A., Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 52 (2003), i3–i17.
2. 2 DiNubile, M.J., Lipsky, B.A., Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 53 (2004), ii37–ii50.
3. 3 Grolman, D.C., Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. Int J Infect Dis 11 (2007), S7–S15.
4. 4 Stevens, D.L., Bisno, A.L., Chambers, H.F., Dellinger, E.P., Goldstein, E.J., Gorbach, S.L., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59 (2014), 147–159.
5. 5 Lipsky, B.A., Weigelt, J.A., Gupta, V., Killian, A., Peng, M.M., Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol 28 (2007), 1290–1298.
6. 6 Edelsberg, J., Berger, A., Weber, D.J., Mallick, R., Kuznik, A., Oster, G., Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 29 (2008), 160–169.
7. 7 Rennie, R.P., Jones, R.N., Mutnick, A.H., SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 45 (2003), 287–293.
8. 8 Hatoum, H.T., Akhras, K.S., Lin, S.J., The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis 64 (2009), 305–310.
9. 9 Nathwani, D., Eckmann, C., Lawson, W., Solem, C.T., Corman, S., Stephens, J.M., et al. Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe. BMC Infect Dis 14 (2014), 476–486.
10. 10 Pfizer Inc. (Wyeth Pharmaceuticals). Tygacil® package insert. 2013, Pfizer Inc, Philadelphia, PA Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s 026s031lbl. pdf (accessed September 28, 2015).
11. 11 European Medicines Agency, Science Medicines Health. Tygacil (tigecycline) update. European Medicines Agency; 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000644/WC500044509.pdf.(accessed September 28, 2015).
12. 12 Namdari, H., Tan, T.Y., Dowzicky, M.J., Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline Evaluation and Surveillance Trial, 2004-2009. Int J Infect Dis 16 (2012), e60–e66.
13. 13 Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 8th ed, 2009, CLSI, Wayne, PA Document M7-A8.
14. 14 Cattoir, V., Dowzicky, M.J., A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012. Antimicrob Resist Infect Control 3 (2014), 36–44.
15. 15 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 25th ed., 2015, CLSI, Wayne, PA Document M100-S25.
16. 16 Pfizer Inc. (Wyeth Pharmaceuticals Inc.). Tygacil® product insert. 2011, Pfizer Inc, Philadelphia, PA Available at: http://www.pfizerpro.com/hcp/tygacil (accessed May 5, 2015).
17. 17 Sader, H.S., Farrell, D.J., Jones, R.N., Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents 36 (2010), 28–32.
18. 18 van Duijn, P.J., Dautzenberg, M.J., Oostdijk, E.A., Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 17 (2011), 658–665.
19. 19 European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2013, ECDC, Stockholm.
20. 20 Tillotson, G.S., Draghi, D.C., Sahm, D.F., Tomfohrde, K.M., Del Fabro, T., Critchley, I.A., Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother 62 (2008), 109–115.
21. 21 Eckmann, C., Lawson, W., Nathwani, D., Solem, C.T., Stephens, J.M., Macahilig, C., et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents 44 (2014), 56–64.
22. 22 Renteria, M.I., Biedenbach, D.J., Bouchillon, S.K., Hoban, D.J., Raghubir, N., Sajben, P., et al. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012. Diagn Microbiol Infect Dis 79 (2014), 54–59.
23. 23 Morales, G., Picazo, J.J., Baos, E., Candel, F.J., Arribi, A., Peláez, B., et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50 (2010), 821–825.
24. 24 Sánchez Garcia, M., De la Torre, M.A., Morales, G., Peláez, B., Tolón, M.J., Domingo, S., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303 (2010), 2260–2264.
25. 25 Farrell, D.J., Mendes, R.E., Ross, J.E., Jones, R.N., Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 65 (2009), 392–402.
26. 26 Jones, R.N., Kohno, S., Ono, Y., Ross, J.E., Yanagihara, K., ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 64 (2009), 191–201.
27. 27 Ross, J.E., Farrell, D.J., Mendes, R.E., Sader, H.S., Jones, R.N., Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. J Chemother 23 (2011), 71–76.
28. 28 Mendes, R.E., Hogan, P.A., Streit, J.M., Jones, R.N., Flamm, R.K., Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother 69 (2014), 1582–1588.
29. 29 Sader, H.S., Jones, R.N., Stilwell, M.G., Dowzicky, M.J., Fritsche, T.R., Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 52 (2005), 181–186.
30. 30 Hawser, S.P., Badal, R.E., Bouchillon, S.K., Hoban, D.J., Biedenbach, D.J., Cantón, R., et al. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int J Antimicrob Agents 41 (2013), 224–228.
31. 31 Hawser, S.P., Bouchillon, S.K., Lascols, C., Hackel, M., Hoban, D.J., Badal, R.E., et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 55 (2011), 3917–3921.
32. 32 Peleg, A.Y., Seifert, H., Paterson, D.L., Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21 (2008), 538–582.
33. 33 Zavascki, A.P., Carvalhaes, C.G., Picao, R.C., Gales, A.C., Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8 (2010), 71–93.
34. 34 Gales, A.C., Castanheira, M., Jones, R.N., Sader, H.S., Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 73 (2012), 354–360.
35. 35 Turner, P.J., Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 60 (2008), 185–192.
36. 36 Morfín-Otero, R., Alcántar-Curiel, M.D., Rocha, M.J., Alpuche-Aranda, C.M., Santos-Preciado, J.I., Gayosso-Vázquez, C., et al. Acinetobacter baumannii infections in a tertiary care hospital in Mexico over the past 13 years. Chemotherapy 59 (2013), 57–65.